11 Nov 2008   |   News

New technology for improving propetin drugs


Licensing Opportunity

PolyTherics Ltd has developed new pegylation technology for extending the life of protein drugs and improving their properties. The company is now looking for partnerships with biopharmaceutical product-focused companies for the exploitation of its new technologies.

The company says the development enables the targeted, controlled pegylation of practically any recombinant protein. CEO Keith Powell will describe the advances at the BIO-Europe Conference, being held in Dusseldorf, Germany next week (November 17 – 19).


Never miss an update from Science|Business:   Newsletter sign-up